Editorial: Editor’s challenge: Mohamed Rahouma - how can we optimize the management and treatment of cardiac tumors and cardiac complications of cancer?
Résumé
Editor's challenge: Mohamed Rahouma -how can we optimize the management and treatment of cardiac tumors and cardiac complications of cancer?Cardiac tumors are a heterogenous group of neoplasm that can be primary (benign or malignant), or secondary (metastatic) (1).Understanding their epidemiology on a large scale would significantly benefit treatment algorithms, but to this regard current evidence is scant.Interest in cardiac tumors has been progressively growing, as they are now considered curable conditions that can be detected and surgically excised at an early stage (2).Cancer global survival rate has been steadily increasing due to diagnosis and treatment improvements.Nevertheless, cancer treatment is often associated with adverse cardiac reactions that may also affect the heart.This is also known as cancer therapy-induced cardiotoxicity and may negatively impact cancer survivors' prognosis (3).Therefore, one of the aims of Cardio-oncology is to study the cardiovascular effects of cancer and its treatment.This Research Topic in Frontiers in Oncology comes to shed light on the management and treatment of cardiac tumors and cardiac complications of cancer.Two papers focused on cardiac tumors (Rahouma et al., Hao et al.).An interesting analysis of the Surveillance, Epidemiology, and End Results (SEER) database was conducted on the geographical variation in the United States of malignant cardiac tumors.Despite baseline characteristics differences of cardiac tumor patients exist between regions, none of the geographic areas showed a significant disparity in long- Frontiers in Oncology frontiersin.org
Citer ce document
Accès au document
Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter
Voir l'article sur le site de la revueStatistiques
Consultations : 1
Téléchargements : 0